Kornimate/medical-research-clean huggingface dataset:
pcos and us cavitation

Conditions: PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries

Summary: polycystic ovary syndrome (pcos) is the most common endocrine disorder in women of reproductive age. women with this syndrome may have infrequent menstrual periods or amenorrhea and excess androgen levels. the ovaries develop numerous small follicles and fail to ovulate on a regular basis, with subsequent subfertility in those women that wish to conceive. recent research stated that interventions aiming to improve qol among infertile women with pcos should focus on alleviating infertility-related stress, especially among women with high bmi. so, the purpose of this study is to investigate the effect of ultrasound cavitation combined with aerobic exercise on menstrual irregularity and infertility related stress in women having pcos.


Eligibility criteria:
inclusion criteria all women in this study will be on the following criteria: * their ages will range from 20-35 years. * they will be diagnosed with pcos by gynecologist. * doesn't receive any treatment for menstrual regularity and fertility during the study. * bmi above 25kg/m²and less than 35kg/m². * waist /hip ratio \<.88. exclusion criteria women will be excluded if they have one of the following criteria: * skin diseases that prevent the application of cavitation. * severe cardiovascular disease. * other endocrine disordered (hypothyroidism hyperprolactinemia). * patients that who take hormonal treatment within the last 3 months before the study.
a proof of concept study of the safety, tolerability, and efficacy of avastin (bevacizumab) in patients with chemo-naive chronic lymphocytic leukemia

Conditions: Lymphocytic Leukemia, Chronic

Summary: this single arm study evaluated the bone marrow response, safety, and tolerability of 6 months treatment with avastin (bevacizumab) monotherapy in patients with chronic lymphocytic leukemia. patients received 8 cycles (21 days duration) of avastin monotherapy (15mg/kg) with 6 months of follow-up.


Eligibility criteria:
inclusion criteria: * male or female patients, ≥ 18 years of age. * b-chronic lymphocytic leukemia not yet requiring treatment. * eastern cooperative oncology group (ecog) performance status 0-2. * no previous treatment of chronic lymphocytic leukemia (cll) by chemotherapy, radiotherapy, or immunotherapy. * life expectancy \> 6 months. exclusion criteria: * central nervous system (cns) involvement by lymphoma or any evidence of spinal cord compression. * computed tomography (ct) scan based evidence of tumor invading major blood vessels. * gastrointestinal (gi) tract involvement by cll. * active viral, bacterial, or fungal infection. * uncontrolled hypertension, cerebrovascular accident/stroke (≤ 6 months prior to randomization), myocardial infarction (≤ 6 months prior to randomization), unstable angina (≥ new york heart association (nyha) grade iv), thrombosis within 6 months before enrollment, nyha grade ii congestive heart failure, or serious cardiac arrhythmia requiring ongoing medication.
colistin monotherapy vs colsitin-fosfomycine in crab infection

Conditions: Infection Due to Carbapenem Resistant Acinetobacter

Summary: the goal of this clinical trial is to evaluate the efficacy of colistin compared with colistin plus fosfomycin against carbapenem-resistant acinetobacter baumanii infection in thailand. the main questions it aims to answer the following main questions: 1. which group has better clinical response at end of treatment 2. which group has better clinical response at 72 hours and micrological cure at 72 hours and at end of treatment

participants will be randomized in a 1:1 ratio to receive a combination of intravenous colistin plus intravenous fosfomycin (combination group) or colistin alone (monotherapy group) to determine if monotherapy or combination therapy has a better outcome.

Eligibility criteria:
inclusion criteria: * ≥ 20 years old patients who have crab infections (pneumonia, urinary tract infection, skin and soft tissue infection, bloodstream infection) * able to provide informed consent or having a legal proxy who can provide informed consent in case the subject is unable to provide consent on his own exclusion criteria: * minimum inhibitory concentration (mic) of colistin \> 2 mg/l * complicated infection with inadequate source controlled * intracranial infection * infective endocarditis * intraabdominal infection * bone and joint infection * allergic to or have contraindication(s) to any treatment regimen in the study * polymicrobial infection with carbapenem-resistant psuedomonas aeruginosa, carbapenem-resistant enterobacterales (cre), vancomycin-resistant enterococcus (vre) * pregnancy * previous treatment with colistin or fosfomycin more than 96 hours * life expectancy of 24 hour or less * refusal to participate in the study * hospice treatment

Keywords: carbapenem resistant acinetobacter baumanni crab colistin fosfomycin
colesevelam as add-on to pioglitazone therapy for type 2 diabetes mellitus

Conditions: Type 2 Diabetes Mellitus

Summary: the current study investigates colesevelam as add-on therapy to pioglitazone to improve glycemic control in subjects with type 2 diabetes mellitus not adequately controlled with pioglitazone monotherapy or pioglitazone in combination with either metformin or a sulfonylurea. the study will evaluate if colesevelam add-on to pioglitazone therapy for type 2 diabetes mellitus will be safe, well tolerated, and efficacious.


Eligibility criteria:
inclusion criteria: * diagnosis of type 2 diabetes mellitus * inadequate glycemic control on a stable dose (at least 2 months prior to screening) of pioglitazone at 30 or 45 mg/day, with or without one or two other oral antidiabetic medications \[metformin or a sulfonylurea, or dipeptidyl peptidase (dpp-iv) inhibitor\] * hemoglobin a1c (hba1c) \>= 7.5% and =\< 9.5% at screening * fasting plasma glucose =\<240 mg/dl at randomization (week 0/day 1). * male or female \>= 18 years of age. * women of childbearing potential must be using an adequate method of contraception as detailed per-protocol * fasting c-peptide level \>0.5 ng/ml at screening * clinically stable in regards to medical conditions other than type 2 diabetes * concomitant medications are at stable doses for at least 30 days prior to enrollment, and are not anticipated to need adjustment during the study period exclusion criteria: * history of type 1 diabetes and/or history of ketoacidosis * history of bowel obstruction * history of hypertriglyceridemia-induced pancreatitis * fasting serum triglyceride concentration \>500 mg/dl * history of dysphagia, swallowing disorders, gastroparesis, other gastrointestinal motility disorders, major gastrointestinal surgery * history of insulin use \>= 2 weeks duration during the previous 3 months or a total of \>2 months insulin therapy at any time prior to screening * treatment with bile acid sequestrants, including colesevelam within 3 months prior to screening * female subject who is pregnant or breastfeeding * history of unstable angina, myocardial infarction, cerebrovascular accident, transient ischemic attack, or any revascularization within 6 months prior to screening
white light scanning to aid body contouring: a pilot project

Conditions: Lipodystrophy; Body Dysmorphic Disorders

Summary: a white light scanner can more accurately measure body contouring subjects than standard anthropomorphic methods.

a 3-d digital body camera that employs non-intrusive white light phase profilometry and 24 coordinated charge-coupled cameras scans and produces a "point cloud" image of the subject. the result of the two-minute scan process is an accurate three-dimensional body model of the subject, consisting of over 1.2 million surface points. the point cloud is compressed to provide programmable measurement extraction profiles (mep's) that automatically extracts linear and circumferential measurements. subjects are scanned and anthropometrically measured pre-operatively, and at 3, 6 and 9 months post-op.

Eligibility criteria:
inclusion criteria: * all healthy preoperative body contouring subjects between 18-65 years old are potentially included in this study. exclusion criteria: * pregnant, nursing,or have a history of epilepsy. * individuals under 18 years old; * problems reading or understanding spoken instructions; * are in jail or in a "locked ward"; * are a student or an employee of evms; or * are chemically-dependent.

Keywords: anthropometric white light scanner extraction profiles body lipodystrophy
a pilot study to evaluate the contribution of the saphenous nerve in ankle pain of patients with degenerative joint disease of the ankle

Conditions: Degenerative Joint Disease of the Ankle

Summary: to assess the pain scores before and after saphenous nerve block placement in patients with degenerative joint disease of the ankle


Eligibility criteria:
inclusion criteria: * patients evaluated with osteoarthritis who are surgical candidates for ankle fusion or total ankle replacement. * registered patients at mayo clinic in florida with scheduled visit to see dr.whalen exclusion criteria: * patients with lower extremity diabetic neuropathy * history of prior trauma of ankle with residual nerve injury * current medication of pregabalin or gabalin * allergy to lidocaine.

Keywords: ankle saphenous nerve block
an explorative pilot study of a new mobile phone application measuring eye parameters of eyes in patients with sud

Conditions: Drug Abuse

Summary: this will be a pre-market, explorative, early feasibility, pilot, controlled clinical investigation designed to collect initial clinical data for previct drugs.

this second early feasibility study will give valuable information on the usability of previct drugs once being used in the intended population, i.e, patients with confirmed substance use disorder (sud). it will also give valuable information on the feasibility of previct drugs function to measure pupils and eye movements in this population including evaluating the safety when using the device.

Eligibility criteria:
inclusion criteria: * signed informed consent form * male and female * a recurrent visitor at sprututbytesprogrammet in uppsala defined as visited the clinic within the last three (3) months * sud in accordanve with dsm-5 criteria according to investigator/designee judgement * age 18 and above * negative urine pregnancy test for all fertile women * been informed of the nature, the scope, and the relevance of the clinical investigation * voluntarily agreed on participation and has duly singed the informed consent form exclusion criteria: * participating in another clinical investigation which may affect the study outcome according to clinical judgement * pregnancy or lactating * blind * deaf * any ecg dangerous arrythmia according to the investigator or designee judgement * any disease or condition that may influence pupillary reflexes based on clinical judgement * undergone eye surgery that may influence pupillary reflexes based on clinical judgement * not able to read or understand the local language * any planned travel or treatment which will make it impossible to participate according to the investigator or designee * any other condition that as judged by the investigator may make the follow-up or investigation inappropriate * that according to the declaration of helsinki is deemed unsuitable for study enrolment
creativity group for borderline personality disorder

Conditions: Borderline Personality Disorder

Summary: the investigators hypothesize that a creativity skills group for borderline personality disorder can reduce symptoms of bpd, depression, and anxiety.


Eligibility criteria:
inclusion criteria: * 18 years of age or older * participant self-reports clinical diagnosis of borderline personality disorder * currently seeing an individual therapist on a regular basis

Keywords: borderline personality disorder borderline personality borderline
longitudinal registry including patients treated with heavy particles

Conditions: Cancer; Oncology; Radiation Exposure; Radiotherapy Side Effect; Radiation Toxicity; Rare Disease

Summary: the purpose of this registry is to collect retrospective and prospective standardized data of patients treated with particle therapy, either with protons or carbon ions, at the national center for oncological hadrontherapy (cnao) based in pavia. by keeping track of the patients treated, it will allow the investigators to periodically analyze and evaluate data collected of daily clinical activity. this will help gathering more information on the results of particle therapy and will provide the basis for in depth evaluation of patients' outcome with respect to the delivered treatment.

hadrontherapy is a unique radiotherapy (rt) that uses positively charged particles, namely protons and carbons, rather than photons used in conventional rt, to treat cancer. particle therapy represents a coming together of physics research applied to oncology and it is currently the most advanced form of radiotherapy for the treatment of tumors that are particularly radio resistant or located nearby sensitive structures.the strength of hadrontherapy lies in the unique physical and radiobiological properties of these particles. indeed, protons and carbon ions have several biological advantages compared to conventional photon radiotherapy. in this scenario we aim at constructing a patient registry to retrospectively and prospectively collect real-world data on all cancer patients treated at cnao, either with protons or carbon ion radiation, independently of their disease (multiple cohorts will be included) for which they were treated. we aim at collecting data on the natural history of the disease (how the disease presents, develops and progress, its association with other conditions). those data will allow us to assess prognostic and predictive factors to evaluate treatment effects and toxicities and to provide evidence of the role of radiation oncology in a multidisciplinary approach. such registry will be used to generate clinical evidence and high-quality data that could better define the indications for heavy particles therapy and become a resource for the wider scientific community.

Eligibility criteria:
inclusion criteria: * patients treated with heavy particles at fondazione cnao, pavia * patients who have the ability to understand and be willing to sign a written informed consent document exclusion criteria: * patients or legal guardians who are unable to understand informed consent document

Keywords: hadrontherapy oncology cancer radiotherapy protons carbon ions heavy ions rare cancer
testing the effectiveness of the interactive tutorial of the home macular perimeter (hmp)

Conditions: Age Related Macular Degeneration

Summary: demonstrate the ability of the current interactive tutorial and 1-800 support to teach an amd patient to use the hmp device.

the pilot study purpose is to demonstrate that the tutorial which is a part of the device software, is giving sufficient training for the intended users.

Eligibility criteria:
inclusion criteria: * capable and willing to sign a consent form and participate in the study * subjects diagnosed as intermediate amd in at least one eye * age \>50 years * va with habitual correction \>20/60 in the study eye * ability to speak, read and understand instructions in hebrew * familiar with computer usage exclusion criteria: * evidence of macular disease other than amd or glaucoma in the study eye * presence of any significant media opacity that precludes a clear view of the macular area as identified in the study eye by biomicroscopy, cfp. * any non-macular related ocular surgery performed within 3 months prior to study entry in the target eye * participation in another study with the exclusion of areds study * patients diagnosed with geographic atrophy (ga)

Keywords: hmp, php, amd, cnv, hphp
a study of insulin peglispro and glargine on fats in participants with type 1 diabetes

Conditions: Diabetes Mellitus, Type 1

Summary: this study has two parts. each participant will receive a daily injection of insulin peglispro during one treatment period and a daily injection of insulin glargine during the other treatment period. each treatment period is 3 to 4 weeks and is followed by procedures to look at how the body uses or stores fats while taking each study drug.


Eligibility criteria:
inclusion criteria: * type 1 diabetic for more than 1 year with glycated hemoglobin (hba1c) of less than 8.5% * otherwise fit and healthy * non smoker exclusion criteria: * taking medication or supplements other than insulin to control diabetes. * suffered a hypoglycemic event in the last 12 months that required hospitalization or have poor awareness of hypoglycemia * taking fibrates, thyroid replacement therapy, testosterone, beta blockers or systemic corticosteroids
application of auricular point sticking in patients with taste alteration

Conditions: Dysgeusia; Acupressure; Chemotherapy Effect

Summary: to explore the intervention effect of auricular point sticking on chemotherapy-induced taste alterations in cancer patients, and analyze its relationship with quality of life, nutritional status and psychology of patients.

taste alteration is a common adverse reaction in patients with chemotherapy. the incidence of taste alteration varies with chemotherapy drugs, ranging from 36% to 84%, among which platinum chemotherapeutic drugs are most likely to cause severe taste alteration. the taste alteration does not pose a serious threat to the life of patients, so it is often ignored by patients and medical staff. dysgeusia is positively correlated with the loss of appetite, which can directly lead to the loss of appetite and insufficient intake of nutrients in patients, and even stimulate patients' anxiety, psychological pain and other negative emotions. in severe cases, it can cause malnutrition, reduce the chemotherapy compliance of cancer patients, and ultimately reduce the quality of life of patients. therefore, for patients with platinum chemotherapy, it is necessary to pay close attention to the change of taste during chemotherapy, and apply effective nursing interventions to pay attention as soon as possible, so as to improve the quality of life of patients.

Eligibility criteria:
inclusion criteria: 1. patients with malignant tumors diagnosed by histopathology or pathology; 2. age ≥18 years old; 3. patients who received platinum-based chemotherapy and completed at least one cycle of chemotherapy; 4. according to the chemotherapy-induced taste changes scale (citas), the score of patients was ≥6; 5. patients voluntarily participated in the treatment with good compliance and adherence. exclusion criteria: 1. patients with treatment plan adjustment or concurrent radiotherapy; 2. patients with abnormal taste and malnutrition caused by various reasons before chemotherapy; 3. patients with inflammation of the external ear or eczema, ulcers, chilblain in the pressing area; 4. allergic or intolerant to adhesive stickers; 5. those who were lost to follow-up or withdrew voluntarily; 6. patients enrolled in other studies at the same time.
peridontal and intestinal microbiota in patients with gingival scarring pemphigoid

Conditions: Pemphigoid, Benign Mucous Membrane; Gingivitis Hyperplastic

Summary: patients suffering from mucous membrane pemphigoid with desquamative gingivitis (mmpg) generally present a more degraded periodontal condition compared with controls. bullous disease could represent a risk factor for plaque-induced periodontal disease, and vice versa. indeed, the dysbiotic periodontal microbiota could aggravate the gingival damage specific to mmp, either directly by activating inflammatory pathways, or indirectly by degrading cellular and matrix components. on the other hand, areas of erosive gingiva generated by the autoimmune process could increase the virulent power of periodontal pathobionts, by representing accessible, nutrient-rich connective surfaces. moreover, in recent years, bacterial studies based on a high-throughput metagenomic approach have suggested the existence of a relationship between the oral and intestinal microbiota in patients with degraded periodontal conditions and suffering from autoimmune inflammatory diseases (inflammatory bowel disease, acute graft-versus-host disease). this relationship can also be envisaged in mmpg patients who meet the conditions that allow this type of pathological process to occur: autoimmune disease; disruption of the gingival epithelial barrier in erosive gingival areas (increasing the risk of antigen exposure); large amounts of thick plaque; degraded periodontal condition with the presence of numerous periodontal pockets from which periodontopathogenic bacteria can translocate intra-tissularly and cause distant adverse consequences. the main aim of this observational, multicentre, case-control, matched study is to compare the composition of the periodontal microbiota between mmpg patients and control patients (arm 2 and arm 3). the secondary objectives are to compare the composition of periodontal and intestinal microbiota in cases and control patients (arm 2 and arm 3), to compare periodontal microbiota composition in cases and control patients (arm 2) according to periodontitis severity, and to compare gut microbiota composition between cases and control patients (arm 2 and arm3). to date, no such study exists.


Eligibility criteria:
inclusion criteria: adults (over 18), non-smokers arm 1 * mmpg (initial, persistent despite medical treatment, recurrent), periodontitis arm 2 * non-mmpg, periodontitis, matched to cases on age, gender and severity of periodontitis arm 3: - non-mmpg, healthy periodontal conditions, matched to cases on age and gender exclusion criteria: * antibiotic therapy and mechanical periodontal treatment within 3 months prior to study, other chronic general illness of immune or digestive origin